Barclays
RARE icon

Barclays’s Ultragenyx Pharmaceutical RARE Stock Holding History

Barclays’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200,000
Closed -$4.6M – 5361
2025
Q4 		$4.6M Hold
200,000
– – ﹤0.01% 2280
2025
Q3 		$6.02M Sell
200,000
-191,600
-49% -$5.75M ﹤0.01% 2052
2025
Q2 		$14.2M Buy
391,600
+351,700
+881% +$12.7M ﹤0.01% 1325
2025
Q1 		$1.44M Buy
+39,900
New +$1.66M ﹤0.01% 2886
2024
Q3 		– Sell
-174,000
Closed -$7.15M – 5436
2024
Q2 		$7.15M Buy
174,000
+144,000
+480% +$6.15M ﹤0.01% 1338
2024
Q1 		$1.4M Hold
30,000
– – ﹤0.01% 2862
2023
Q4 		$1.43M Buy
+30,000
New +$1.16M ﹤0.01% 3172
2019
Q2 		– Sell
-50,000
Closed -$3.47M – 7208
2019
Q1 		$3.47M Buy
+50,000
New +$2.86M ﹤0.01% 1996
2018
Q4 		– Sell
-700
Closed -$53K – 7266
2018
Q3 		$53K Buy
700
+600
+600% +$48.8K ﹤0.01% 6047
2018
Q2 		$8K Hold
100
– – ﹤0.01% 6617
2018
Q1 		$5K Hold
100
– – ﹤0.01% 6795
2017
Q4 		$5K Buy
+100
New +$4.9K ﹤0.01% 6672
2017
Q3 		– Sell
-600
Closed -$37K – 7005
2017
Q2 		$37K Sell
600
-9,300
-94% -$560K ﹤0.01% 5508
2017
Q1 		$671K Buy
9,900
+8,900
+890% +$678K ﹤0.01% 3113
2016
Q4 		$70K Buy
+1,000
New +$70.9K ﹤0.01% 4964

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Barclays's RARE Position: Q1 2026 in Review

Barclays reduced its Ultragenyx Pharmaceutical (RARE) stake by 30% in Q1 2026, selling an estimated $2.46M and leaving 249,807 shares worth $5.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Barclays first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Barclays held 249,807 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q1 2026.
  • Barclays sold 109,341 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.46M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1791 holding.
  • Barclays first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Barclays's Ultragenyx Pharmaceutical position peaked at $12.8M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.